Submission of Press Release on financial results of the Company for the first quarter ended June 30, 2026.
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 05 Aug 2026, 08:02 PM IST · BSE ID: b866f5ca-1869-4ed2-8c83-79c149a71848
View Original BSE Filing (PDF)
💡
In Simple Terms
Aurobindo Pharma reported higher sales and profits for the first quarter of fiscal year 2027.
🤖 AI Summary
- Aurobindo Pharma reported Q1 FY27 Net Profit of INR 1,032 Cr, a 25.2% increase YoY.
- Revenue from Operations for Q1 FY27 reached INR 9,150 Cr, up 16.3% from Q1 FY26.
- US revenue grew by 8.1% YoY to INR 3,770 Cr; Europe revenue increased 25.6% YoY to INR 2,937 Cr.
- Growth Markets revenue rose 37.7% YoY to INR 1,063 Cr, contributing to overall formulations growth.
- The company received final approval for 10 products from the USFDA during the quarter.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations
INR 9,150 Cr
16.3%
Net Profit for the period
INR 1,032 Cr
25.2%
EBITDA (Before Forex and Other Income and exceptional items)
INR 1,924 Cr
20.0%
US revenue
INR 3,770 Cr
8.1%
Europe revenue
INR 2,937 Cr
25.6%
Growth Markets revenue
INR 1,063 Cr
37.7%
ARV revenue
INR 330 Cr
-6.9%
🏢 How This Affects the Company
The company's diverse product portfolio drove growth across key markets including the US, Europe, and Growth Markets, indicating expanding market penetration. New product approvals from USFDA support future revenue streams.
Consolidated revenue increased, leading to a 25.2% rise in Net Profit. EBITDA margin expanded to 21.0% from 20.4% YoY. The company reported a net cash position of USD 42mn after recent acquisitions and buyback.
Robust performance across geographies, with significant growth in Europe and Growth Markets, demonstrates effective operational execution. The launch of 10 products indicates ongoing R&D to market efforts.
ARV revenue decreased by 6.9% YoY to INR 330 Cr, indicating a potential concentration risk if not balanced by growth in other segments.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, with the increase in net profit indicating enhanced earnings for the period.
🔍
Management Signal
Management expressed confidence in disciplined execution and a diversified product portfolio to achieve long-term growth objectives.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — observe sustained growth in key markets.
USFDA approval pipeline — track new product launches and approvals.
Impact of Lannett acquisition — monitor integration and financial contributions.
LOW RISK
No new significant risks were identified; minor decline in one segment.
💡 Investor Takeaway
Aurobindo Pharma reported Q1 FY27 Net Profit of INR 1,032 Cr, a 25.2% increase over INR 824 Cr in Q1 FY26. Revenue from Operations grew 16.3% YoY to INR 9,150 Cr from INR 7,868 Cr, driven by strong performance in Europe and Growth Markets.
⚖️ Strengths & Concerns
✅ Positives
- Revenue from Operations increased by 16.3% YoY to INR 9,150 Cr, reflecting growth across various business segments.
- Net Profit for the period rose 25.2% YoY to INR 1,032 Cr, demonstrating improved profitability compared to the prior year.
⚠️ Concerns
- ARV revenue decreased by 6.9% YoY to INR 330 Cr, indicating a decline in this specific business segment.
- EBITDA margin before R&D decreased by 63 bps YoY to 24.1%, suggesting a slight compression in core operating efficiency.
📅 Company Track Record
Aurobindo Pharma reported a 31.85% rise in Profit After Tax to ₹7,372.2 million for Q1 FY26, as per a previous filing on August 5, 2026. This indicates a consistent trend of profit growth in recent quarters.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Aurobindo Pharma's net profit in Q1 FY27?
Aurobindo Pharma's Net Profit for Q1 FY27 was INR 1,032 Cr, representing a 25.2% increase compared to INR 824 Cr in Q1 FY26.
What was Aurobindo Pharma's Revenue from Operations for Q1 FY27?
Aurobindo Pharma's Revenue from Operations for Q1 FY27 was INR 9,150 Cr, an increase of 16.3% from INR 7,868 Cr in Q1 FY26.
How did Aurobindo Pharma's US revenue perform in Q1 FY27?
US revenue for Aurobindo Pharma in Q1 FY27 increased by 8.1% YoY to INR 3,770 Cr (USD 399 million).
How many USFDA approvals did Aurobindo Pharma receive in Q1 FY27?
Aurobindo Pharma received final approval for 10 products from the USFDA during the quarter ended June 30, 2026.
What was Aurobindo Pharma's EBITDA Margin in Q1 FY27?
Aurobindo Pharma's EBITDA Margin for Q1 FY27 was 21.0%, which is a 60 bps increase from 20.4% in Q1 FY26.
Questions based on this BSE filing only. For information purposes.